Skip to main content
Journal ArticleOPEN ACCESS

Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma

  • Hwu P
  • Hamid O
  • Gonzalez R
  • et al.
Annals of Oncology (2016) 27 vi380
DOI: 10.1093/annonc/mdw379.05
N/ACitations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Targeted therapy with MEK inhibitor cobimetinib (C) + BRAF inhibitor vemurafenib (V) in BRAF

Cite

CITATION STYLE

APA

Hwu, P., Hamid, O., Gonzalez, R., Infante, J. R., Patel, M. R., Hodi, F. S., … Sullivan, R. (2016). Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Annals of Oncology, 27, vi380. https://doi.org/10.1093/annonc/mdw379.05

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free